Health Care & Life Sciences » Pharmaceuticals | Sinovac Biotech Ltd.

Sinovac Biotech Ltd. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
72,524.00
63,101.00
67,414.00
72,431.00
174,346.00
229,650
Cost of Goods Sold (COGS) incl. D&A
21,273.00
16,493.00
18,408.00
22,393.00
20,240.00
24,723
Gross Income
51,251.00
46,608.00
49,006.00
50,038.00
154,106.00
204,927
SG&A Expense
42,418.00
46,150.00
46,922.00
56,040.00
108,788.00
160,292
EBIT
8,833.00
458.00
-
6,002.00
45,318.00
44,635
Unusual Expense
57.00
-
-
-
-
-
Non Operating Income/Expense
232.00
1,386.00
1,437.00
6,606.00
112.00
1,002
Interest Expense
3,096.00
3,488.00
1,920.00
1,729.00
1,569.00
1,070
Pretax Income
8,145.00
1,122.00
2,756.00
394.00
45,044.00
46,583
Income Tax
2,225.00
1,458.00
2,985.00
2,664.00
8,339.00
10,472
Consolidated Net Income
10,370.00
336.00
229.00
3,058.00
36,705.00
36,111
Net Income
7,442.00
851.00
688.00
2,934.00
25,807.00
21,782
Net Income After Extraordinaries
7,442.00
851.00
40.00
5,272.00
25,807.00
21,782
Net Income Available to Common
7,442.00
851.00
1,416.00
3,057.00
25,807.00
21,782
EPS (Basic)
0.13
0.02
0.00
0.01
0.45
0.34
Basic Shares Outstanding
55,301.30
55,681.10
56,313.90
56,949.10
57,033.80
64,727.10
EPS (Diluted)
0.13
0.02
0.03
0.01
0.45
0.34
Diluted Shares Outstanding
55,802.30
55,681.10
56,313.90
56,949.10
57,101.20
64,977.60
EBITDA
15,577.00
8,878.00
8,342.00
939.00
49,956.00
49,522
Non-Operating Interest Income
2,168.00
2,685.00
1,155.00
731.00
1,183.00
2,016
Minority Interest Expense
2,928.00
515.00
459.00
124.00
10,898.00
14,329

About Sinovac Biotech

View Profile
Address
No. 15 Zhi Tong Road
Beijing Beijing 102200
China
Employees -
Website http://www.sinovacbio.com
Updated 07/08/2019
Sinovac Biotech Ltd. is a holding and biopharmaceutical company, which engages in the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease. It operates through the Mainland China and Hong Kong geographical segments. Its product pipelines include Healive, Bilive, Anflu, PANFLU.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.